CN116829138A - 肥厚型心肌病治疗剂 - Google Patents

肥厚型心肌病治疗剂 Download PDF

Info

Publication number
CN116829138A
CN116829138A CN202280011367.6A CN202280011367A CN116829138A CN 116829138 A CN116829138 A CN 116829138A CN 202280011367 A CN202280011367 A CN 202280011367A CN 116829138 A CN116829138 A CN 116829138A
Authority
CN
China
Prior art keywords
hypertrophic cardiomyopathy
aminolevulinic acid
salts
esters
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280011367.6A
Other languages
English (en)
Chinese (zh)
Inventor
冈崎康司
冈崎敦子
美野轮治
早乙女秀雄
八塚由纪子
土田胜晴
市野纪子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saitama Medical University
Original Assignee
Saitama Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saitama Medical University filed Critical Saitama Medical University
Publication of CN116829138A publication Critical patent/CN116829138A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280011367.6A 2021-01-25 2022-01-24 肥厚型心肌病治疗剂 Pending CN116829138A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021009754 2021-01-25
JP2021-009754 2021-01-25
PCT/JP2022/002413 WO2022158591A1 (ja) 2021-01-25 2022-01-24 肥大型心筋症治療剤

Publications (1)

Publication Number Publication Date
CN116829138A true CN116829138A (zh) 2023-09-29

Family

ID=82548732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280011367.6A Pending CN116829138A (zh) 2021-01-25 2022-01-24 肥厚型心肌病治疗剂

Country Status (5)

Country Link
US (1) US20240082189A1 (enExample)
EP (1) EP4309651A4 (enExample)
JP (1) JPWO2022158591A1 (enExample)
CN (1) CN116829138A (enExample)
WO (1) WO2022158591A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011016753A (ja) * 2009-07-08 2011-01-27 Sbi Alapromo Co Ltd ５−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤
WO2020059242A1 (ja) * 2018-09-20 2020-03-26 国立大学法人北海道大学 心不全の病態の評価方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1743621B1 (en) 2004-04-28 2014-03-05 Cosmo Oil Co., Ltd. Hair restorer
JP5098051B2 (ja) * 2007-04-05 2012-12-12 Ｓｂｉファーマ株式会社 ミトコンドリア障害脳疾患治療剤及び診断剤
WO2022202477A1 (ja) * 2021-03-23 2022-09-29 国立大学法人九州大学 アントラサイクリン系抗がん剤の副作用の予防剤又は治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011016753A (ja) * 2009-07-08 2011-01-27 Sbi Alapromo Co Ltd ５−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とするがんの予防・改善剤
WO2020059242A1 (ja) * 2018-09-20 2020-03-26 国立大学法人北海道大学 心不全の病態の評価方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E. DOUGLAS WIGLE ET AL.: "Hypertrophic Cardiomyopathy : Clinical Spectrum and Treatment", 《CIRCULATION》, vol. 92, no. 7, 1 October 1995 (1995-10-01), pages 1680 - 1692, XP093209482, DOI: 10.1161/01.CIR.92.7.1680 *
MINGYI ZHAO ET AL: "5-Aminolevulinic acid combined with sodium ferrous citrate ameliorates H2O2-induced cardiomyocyte hypertrophy via activation of the MAPK/Nrf2/ HO-1 pathway", 《AM J PHYSIOL CELL PHYSIOL》, vol. 308, 4 February 2015 (2015-02-04), pages 665 *

Also Published As

Publication number Publication date
US20240082189A1 (en) 2024-03-14
WO2022158591A1 (ja) 2022-07-28
EP4309651A1 (en) 2024-01-24
EP4309651A4 (en) 2024-11-06
JPWO2022158591A1 (enExample) 2022-07-28

Similar Documents

Publication Publication Date Title
JP3955093B2 (ja) 光化学治療における光増感剤としての５−アミノレブリン酸のエステル
BR112018068142B1 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos e kit
JPH06312928A (ja) 抗不整脈作用、鎮痛作用およびマルチ薬剤耐性を示す医薬品並びにその製造法
Morisawa et al. Association of 5-aminolevulinic acid with intraoperative hypotension in malignant glioma surgery
CN118255728B (zh) 化合物的盐型晶型用于治疗射血分数保留的心衰的用途
CN118078801A (zh) 一种四氢-2-(2-苯乙基)色酮衍生物在制备治疗突变肺癌药物中的应用
US20090246145A1 (en) Imaging Correlates of Neurogenesis With MRI
Zhu et al. A novel carbazole-based hydrogen-sulfide donor suppresses seizures and upregulates ATP-sensitive potassium channels
JP5472819B2 (ja) 膀胱がん検出方法
EP2584356B9 (en) Method for detection of urothelial cancer
CN116829138A (zh) 肥厚型心肌病治疗剂
US20230320564A1 (en) Ca ix - nir dyes and their uses
CN108066337B (zh) KB-R7943或Bepridil在制备治疗神经胶质瘤的药物中的应用
US20240335432A1 (en) Therapeutic compound for neuronal ceroid lipofuscinosis
EA022275B1 (ru) Применение рацематов пиноцембрина для получения лекарственных средств для лечения инсульта
ES2941628T3 (es) Método de tratamiento de la fibrosis pulmonar idiopática
JP2022506440A (ja) 肥大型心筋症治療用薬学組成物
CN120957749A (zh) 一种sglt2抑制剂与薄荷醇的组合及其治疗心脏疾病的用途
CN120549901A (zh) 氟西汀在制备治疗癫痫发作或脑损伤药物中的应用
Бойцанюк et al. DIAGNOSTIC METHODS OF FOCAL DEMINERALIZATION TOOTH ENAMEL
CN114869913A (zh) 牙髓干细胞在制备治疗多发性硬化症的药物中的应用
CN105267990B (zh) 一种含有miRNA-873的药物组合物及其用途
EA049838B1 (ru) Мишенный пептид и способ его применения для диагностики злокачественных новообразований центральной нервной системы
JP2025170421A (ja) 全身性硬化症の予防または治療用薬学的組成物
CN113616782A (zh) 鸢尾素在治疗癫痫中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination